Lutetium-177–PSMA-617: Appropriate and Potential Off-Label Utility

Scott Tagawa, MD, MS, FACP, Professor of Medicine and Urology at Weill Cornell Medicine, and an Attending Physician at New York-Presbyterian – Weill Cornell Medical Center, highlights what clinicians must know prior to recommending Lutetium-177–PSMA-617 to patients, and whether there is a clinical cut-off for when patients would or wouldn’t be considered.

View Dr. Tagawa’s other comments on prostate cancer management, including PSMA PET Versus Cross-Sectional Imaging and RLT Administration in the Community Setting.